A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death

Molecular Cancer Therapeutics

Volumn 7, Issue 11, 2008, Pages 3546-3555

  Wood, Tabitha E ^a,b   Dalili, Shadi ^a,b   Simpson, Craig D ^a   Hurren, Rose ^a   Mao, Xinliang ^a   Saiz, Fernando Suarez ^a   Gronda, Marcela ^a   Eberhard, Yanina ^a   Minden, Mark D ^a   Bilan, Philip J ^c   Klip, Amira ^c   Batey, Robert A ^b   Schimmer, Aaron D ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL]THIOUREA; 1 BENZYL 3 [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL]UREA; 4 CHLORO N [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL]BENZAMIDE; CYTOCHALASIN B; DEATH RECEPTOR; DIPYRIDAMOLE; FAS ANTIGEN; FASENTIN; GLUCOSE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER INHIBITOR; INDINAVIR; N [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL] 3 HYDROXYBUTANAMIDE; N [4 CHLORO 3 (TRIFLUOROMETHYL)PHENYL] N METHYL 3 OXOBUTANAMIDE; PHLORETIN; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; GENE EXPRESSION; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; NUTRIENT; PRIORITY JOURNAL;

ANILIDES; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; BINDING SITES; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL LINE, TUMOR; FAS LIGAND PROTEIN; GENE EXPRESSION PROFILING; GLUCOSE; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; MALE; RECEPTORS, DEATH DOMAIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 56249134557     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0569     Document Type: Article

References (40)

1. Wang SL, El-Deiry WS. TRAIL and apoptosis induction by TNF-family death receptors. Oncogene 2003;22:8628-33.
2. Mawji IA, Simpson CD, Hurren R, et al. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst 2007;99:811-22.
3. Plummer R, Attard G, Pacey S, et al. Phase 1 and pharmacokinetic studyof lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-94.
4. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer 2002;2:277-88.
5. Schimmer AD, Thomas MP, Hurren R, et al. Identification of small molecules that sensitize resistant tumor cells to tumor necrosis factor-family death receptors. Cancer Res 2006;66:2367-75.
6. Rudich A, Konrad D, Torok D, et al. Indinavir uncovers different contributions of GLUT4 and GLUT1 towards glucose uptake in muscle and fat cells and tissues. Diabetologia 2003;46:649-58.
7. Dennis G, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003;4.
8. Huang DW, Sherman BT, Tan Q, et al. DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene lists. Nucleic Acids Res 2007;35:W169-75.
9. Lu ML, Kwan T, Yu CJ, et al. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J Biol Chem 2005;280:6742-51.
10. Salas-Burgos A, Iserovich P, Zuniga F, Vera JC, Fischbarg J. Predicting the three-dimensional structure of the human facilitative glucose transporter Glut1 by a novel evolutionary homology strategy: insights on the molecular mechanism of substrate migration, and binding sites for glucose and inhibitory molecules. Biophys J 2004;87:2990-9.
11. Rarey M, Kramer B, Lengauer T, Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol 1996;261:470-89.
12. Bain PJ, LeBlanc-Chaffin R, Chen H, et al. The mechanism for transcriptional activation of the human ATA2 transporter gene by amino acid deprivation is different than that for asparagine synthetase. J Nutr 2002;132:3023-9.
13. Carriere V, Rodolosse A, Lacasa M, et al. Hypoxia and CYP1A1 induction-dependent regulation of proteins involved in glucose utilization in Caco-2 cells. Am J Physiol Gastrointest Liver Physiol 1998;274:G1101-8.
14. Taverna RD, Langdon RG. Reversible association of cytochalasin-B with human erythrocyte-membrane - inhibition of glucose transport and stoichiometry of cytochalasin binding. Biochim Biophys Acta 1973;323:207-19.
15. Gazitt Y. Early decrease of 2-deoxy glucose and α-amino isobutyric acid transport are among the 1st events in differentiating synchronized murine erythroleukemia-cells. J Cell Physiol 1979;99:407-16.
16. Tomida A, Suzuki H, Kim HD, Tsuruo T. Glucose-regulated stresses cause decreased expression of cyclin D1 and hypophosphorylation of retinoblastoma protein in human cancer cells. Oncogene 1996;13:2699-705.
17. Chan DYL, Chen GG, Poon WS, Liu PC. Lovastatin sensitized human glioblastoma cells to TRAIL-induced apoptosis. J Neurooncol 2008;86:273-83.
18. Beletskaya IV, Nikonova LV, Beletsky IP. Cell cycle specificity of Fas-mediated apoptosis in WIL-2 cells. FEBS Lett 1997;412:91-3.
19. Jedema I, Barge RMY, Willemze R, Falkenburg JHF. High susceptibility of human leukemic cells to Fas-induced apoptosis is restricted to G(1) phase of the cell cycle and can be increased by interferon treatment. Leukemia 2003;17:576-84.
20. 1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle 2002;1:82-9.
21. Li Y, Dida F, Iwao A, et al. Cell cycle dependency of caspase activation in Fas-induced apoptosis in leukemia cells. Cancer Sci 2007;98:1174-83.
22. Joost HG, Thorens B. The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members. Mol Membr Biol 2001;18:247-56.
23. Uldry M, Thorens B. The SLC2 family of facilitated hexose and polyol transporters. Pflugers Arch 2004;447:480-9.
24. Czech MP. Characterization of cytochalasin-H-3 B binding to fat-cell plasma-membrane. J Biol Chem 1976;251:2905-10.
25. Murata H, Hruz PW, Mueckler M. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-4.
26. Frerichs H, Ball EG. Studies on metabolism of adipose tissue. XVI. Inhibition by phlorizin + phloretin of insulin-stimulated uptake of glucose. Biochemistry 1964;3:981-5.
27. Graff JC, Hanson DJ, Hatanaka M. Differences in cytochalasin-B inhibition of 3-O-methylglucose uptake between BALB-3T3 cells and a murine sarcoma-virus transformed clone. Int J Cancer 1973;12:602-12.
28. Warburg O. Origin of cancer cells. Science 1956;123:309-14.
29. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891-9.
30. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1α or in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998;394:485-90.
31. Yun H, Lee M, Kim SS, Ha J. Glucose deprivation increases mRNA stabilityof vascular endothelial growth factor through activation of AMP-activated protein kinase in DU145 prostate carcinoma. J Biol Chem 2005;280:9963-72.
32. Laderoute KR, Amin K, Calaoagan JM, et al. 5′-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol 2006;26:5336-47.
33. Christofk HR, Vander Heiden MG, Harris MH, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008;452:230-U74.
34. Younes M, Brown RW, Mody DR, Fernandez L, Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res 1995;15:2895-8.
35. Ogawa J, Inoue H, Koide S. Glucose-transporter-type-I-gene amplification correlates with sialyl-Lewis-X synthesis and proliferation in lung cancer. Int J Cancer 1997;74:189-92.
36. Haber RS, Rathan A, Weiser KR, et al. GLUT1 glucose transporter expression in colorectal carcinoma - a marker for poor prognosis. Cancer 1998;83:34-40.
37. Glinsukon T, Lekutai S. Comparative toxicity in the rat of cytochalasin-B and cytochalasin-E. Toxicon 1979;17:137-44.
38. Halicka HD, Ardelt B, Li X, Melamed MM, Darzynkiewicz Z. 2-Deoxy-D-glucose enhances sensitivity of human histiocytic lymphoma U937 cells to apoptosis induced by tumor-necros is-factor. Cancer Res 1995;55:444-9.
39. Nam SY, Amoscato AA, Lee YJ. Low glucose-enhanced TRAIL cytotoxicity is mediated through the ceramide-Akt-FLIP pathway. Oncogene 2002;21:337-46.
40. Munoz-Pinedo C, Ruiz-Ruiz C, de Almodovar CR, Palacios C, Lopez-Rivas A. Inhibition of glucose metabolism sensitizes tumor cells to death receptor-triggered apoptosis through enhancement of death-inducing signaling complex formation and apical procaspase-8 processing. J Biol Chem 2003;278:12759-68.